This is a StreetInsider.com Premium Only Page

Regeneron (REGN) –

Nov 28, 2023 07:46 AM Regeneron Pharma (REGN) PT Raised to $937 at Jefferies

Nov 27, 2023 05:03 AM Regeneron (REGN) Reports Dupixent Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial

Nov 27, 2023 01:30 AM Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Seriou

Nov 15, 2023 04:03 PM Form 4 REGENERON PHARMACEUTICAL For: Nov 13 Filed by: MURPHY ANDREW J

Nov 14, 2023 05:17 PM Form 4 REGENERON PHARMACEUTICAL For: Nov 10 Filed by: STAHL NEIL

Nov 14, 2023 04:20 PM Form 144 REGENERON PHARMACEUTICAL Filed by: MURPHY ANDREW J

Nov 13, 2023 09:00 AM Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

Nov 8, 2023 04:18 PM Deutsche Bank Starts Regeneron Pharma (REGN) at Hold

Nov 8, 2023 04:08 PM Form 4 REGENERON PHARMACEUTICAL For: Nov 07 Filed by: RYAN ARTHUR F

Nov 7, 2023 04:46 PM Form 144 REGENERON PHARMACEUTICAL Filed by: RYAN ARTHUR F

Nov 6, 2023 04:58 AM Regeneron Pharma (REGN) PT Raised to $915 at DZ Bank

Nov 3, 2023 08:30 AM Regeneron Pharma (REGN) PT Lowered to $914 at Morgan Stanley

Nov 3, 2023 08:07 AM Regeneron Pharma (REGN) PT Raised to $900 at TD Cowen

Nov 3, 2023 07:00 AM Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

Nov 3, 2023 06:50 AM Regeneron Pharma (REGN) PT Raised to $1,066 at Canaccord Genuity

Nov 3, 2023 06:27 AM Regeneron Pharma (REGN) PT Lowered to $837 at RBC Capital

Nov 3, 2023 01:59 AM Raymond James Upgrades Regeneron Pharma (REGN) to Outperform

Nov 2, 2023 04:24 PM Regeneron Pharma (REGN) PT Raised to $797 at Baird

Nov 2, 2023 04:19 PM Regeneron Pharma (REGN) PT Raised to $895 at Piper Sandler

Nov 2, 2023 04:03 PM Form 4 REGENERON PHARMACEUTICAL For: Nov 01 Filed by: McCourt Marion

Nov 2, 2023 08:47 AM Regeneron Pharma (REGN) PT Raised to $907 at UBS

Nov 2, 2023 07:52 AM Starbucks, DoorDash, Roku, Qualcomm rise premarket; Peloton, Moderna fall

Nov 2, 2023 07:23 AM Form 10-Q REGENERON PHARMACEUTICAL For: Sep 30

Nov 2, 2023 07:10 AM Form 8-K REGENERON PHARMACEUTICAL For: Nov 02

Nov 2, 2023 06:48 AM Regeneron sees strong initial demand for higher-dose Eylea

Nov 1, 2023 04:48 PM Form 144 REGENERON PHARMACEUTICAL Filed by: McCourt Marion

Nov 1, 2023 04:00 PM EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema

Oct 26, 2023 04:01 PM Regeneron (REGN) Reports Prelim Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Oct 26, 2023 04:00 PM Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Oct 23, 2023 08:41 AM Regeneron Pharma (REGN) survey shows Eylea franchise in 'good shape' - Piper Sandler

Oct 22, 2023 02:59 PM Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Oct 21, 2023 08:48 AM Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

Oct 20, 2023 05:00 PM Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

Oct 18, 2023 09:30 AM Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

Oct 17, 2023 04:07 PM Form 4 REGENERON PHARMACEUTICAL For: Oct 13 Filed by: Zoghbi Huda Y

Oct 15, 2023 06:05 PM Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Oct 13, 2023 04:02 PM Form 144 REGENERON PHARMACEUTICAL Filed by: Zoghbi Huda Y

Oct 11, 2023 09:00 AM Regeneron Pharma (REGN) PT Raised to $915 at Morgan Stanley

Oct 5, 2023 04:05 PM Form 8-K REGENERON PHARMACEUTICAL For: Oct 05

Oct 5, 2023 09:43 AM Regeneron (REGN) Presents Results from Two-year Results from Pivotal PULSAR Trial of EYLEA HD

Oct 5, 2023 09:43 AM EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA

Oct 3, 2023 04:04 PM Form 4 REGENERON PHARMACEUTICAL For: Oct 02 Filed by: McCourt Marion

Oct 3, 2023 03:49 PM Form 144 REGENERON PHARMACEUTICAL Filed by: Tessier-Lavigne Marc

Oct 3, 2023 07:02 AM Regeneron (REGN) and Intellia (NTLA) Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

Oct 3, 2023 07:00 AM Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

Oct 2, 2023 04:19 PM Form 144 REGENERON PHARMACEUTICAL Filed by: McCourt Marion

Sep 29, 2023 08:31 AM Regeneron (REGN) Reports Odronextamab BLA Accepted for FDA Priority Review

Sep 29, 2023 08:30 AM Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

Sep 28, 2023 04:05 PM Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

Sep 26, 2023 01:29 AM Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review